Prescription medication · 5-HT3 Receptor Antagonist (Antiemetic)

palonosetron

Also sold as Aloxi. Palonosetron is used to prevent nausea and vomiting caused by cancer chemotherapy.

Data updated 2026-05-15

3,330
FDA reportsLightly reported
In shortage
FDA status

What the data shows

palonosetron (Aloxi) is a prescription 5-HT3 Receptor Antagonist (Antiemetic), among the least-reported drugs the FDA tracks (3,330 FDA reports).

Reporting volume reflects how widely a drug is used and studied, not how dangerous it is, a FAERS report documents a temporal association, never proof of cause.

palonosetron (Aloxi) is a prescription 5-HT3 Receptor Antagonist (Antiemetic). Palonosetron is used to prevent nausea and vomiting caused by cancer chemotherapy.

Palonosetron is a medicine that helps prevent nausea and vomiting. It is often used before, during, and after chemotherapy or surgery.

Drug Shortage Alert

palonosetron is currently listed as to be discontinued by the FDA. Affected manufacturer: Teva Pharmaceuticals USA, Inc..

View all drug shortages →
View Alternatives → Compare with Another Drug → Full Side Effects Report →

What it does

Palonosetron is used to prevent nausea and vomiting caused by cancer chemotherapy.

Common side effects

Headache, Constipation

Key warnings

Palonosetron can cause serious allergic reactions, including anaphylaxis.

The sections below are summarized in plain English from palonosetron's FDA-approved prescribing information. They describe what the official label says, and are not personal medical advice.

How It Works

Palonosetron blocks a natural substance in your body called serotonin. Serotonin can trigger nausea and vomiting. By blocking serotonin, palonosetron helps prevent these symptoms.

Side Effects (from patient reports)

Based on 3,330 FDA adverse event reports.

Most-reported reactions

Adverse reactions in FAERS for palonosetron, by number of reports

reports

What this shows Bars show how often each reaction was reported, not how likely it is to happen, a report records a temporal association, never proof that the drug caused it.

Source FDA Adverse Event Reporting System (FAERS) As of 2025

Reports over time

Adverse-event reports filed for palonosetron each year to the FDA Adverse Event Reporting System (FAERS).

0100200300400 20042007201020132016201920222025 366

Year-to-year volume tracks usage, prescribing, and scrutiny, not a change in per-patient risk. Source: FDA FAERS.

Where palonosetron sits

palonosetron has more FDA adverse-event reports than 20% of the drugs FAERS tracks. A high position reflects how widely a drug is used and watched, not how dangerous it is.

fewest reports most reports

Percentile across all drugs PlainMeds tracks by FAERS report volume. The dot is palonosetron; the line is the median (50th percentile).

FDA Adverse Event Report Analysis

Detailed analysis of 3,330 reports from the FDA Adverse Event Reporting System (FAERS). Reports span 2004–2025.

Total Reports

3,330

Reports Mentioning Death

519

15.6% of reports — not proof of cause

Hospitalization Reports

1,660

Top Indication

Product Used For Unknown Indication

Gender Distribution

Female 1,806 (59%)
Male 1,271 (41%)

Age Distribution

0–17 69
18–44 288
45–64 1,245
65–74 803
75+ 358

Most Reported Adverse Reactions (FAERS)

# Reaction Reports
1 NAUSEA 399
2 FATIGUE 249
3 FEBRILE NEUTROPENIA 249
4 DIARRHOEA 246
5 VOMITING 246
6 NEUTROPENIA 245
7 ALOPECIA 223
8 DYSPNOEA 194
9 ANAEMIA 189
11 DEATH 174
12 DECREASED APPETITE 166
13 PYREXIA 164
14 ASTHENIA 151
15 THROMBOCYTOPENIA 142
16 CONSTIPATION 135

Reactions in Death Reports

DEATH 174
FATIGUE 48
NAUSEA 43
DIARRHOEA 42
DISEASE PROGRESSION 40
PNEUMONIA 40
FEBRILE NEUTROPENIA 35
ANAEMIA 34
ASTHENIA 31
SEPSIS 30

Reactions in Hospitalization Reports

FEBRILE NEUTROPENIA 221
NAUSEA 173
NEUTROPENIA 155
VOMITING 134
ANAEMIA 122
DIARRHOEA 122
PYREXIA 115
DYSPNOEA 98
DECREASED APPETITE 91
PNEUMONIA 91

Source: FDA FAERS (Adverse Event Reporting System) Reports are voluntary and do not establish causation

Serious Warnings

Palonosetron can cause serious allergic reactions, including anaphylaxis. Tell your doctor right away if you have any signs of an allergic reaction, such as hives, difficulty breathing, or swelling of your face, lips, tongue, or throat. Palonosetron can also cause serotonin syndrome, especially if you are taking other medicines that affect serotonin. Symptoms may include agitation, hallucinations, fast heart rate, fever, and muscle stiffness.

Common Questions

How quickly does palonosetron work?
Palonosetron starts working before your chemotherapy or surgery begins to prevent nausea and vomiting.
Can I take palonosetron at home?
No, palonosetron is given as an injection by a healthcare provider.
What should I avoid while taking palonosetron?
Talk to your doctor about any other medicines you are taking, especially those that can affect serotonin levels.
Will palonosetron make me sleepy?
Drowsiness is not a common side effect, but some people may experience dizziness.
Can palonosetron be used for morning sickness?
Palonosetron is not typically used for morning sickness. Talk to your doctor about other options.
Is palonosetron a steroid?
No, palonosetron is not a steroid. It is a serotonin-3 receptor antagonist.
Can I drink alcohol while taking palonosetron?
Talk to your doctor about drinking alcohol while taking palonosetron.
What if I am allergic to similar medications?
Tell your doctor if you are allergic to any similar medications before receiving palonosetron.
How long does palonosetron stay in my system?
Palonosetron has a long half-life, meaning it stays in your system for a while. Ask your doctor for more specific information.
Can palonosetron cause heart problems?
Some people have experienced heart rhythm changes. Tell your doctor if you have any heart problems.
What are the common side effects of palonosetron?
The registry lists Headache, Constipation among the most-reported FAERS reaction terms for palonosetron. The compiled record contains 3,330 FDA adverse-event reports. These counts are not an individual symptom assessment.
What drug class is palonosetron?
palonosetron belongs to the 5-HT3 Receptor Antagonist (Antiemetic) drug class. It requires a prescription (Rx). Palonosetron is used to prevent nausea and vomiting caused by cancer chemotherapy.
What pregnancy or breastfeeding source fields are listed for palonosetron?
The FDA label for palonosetron contains product-specific pregnancy or breastfeeding language. PlainMeds does not apply that source text to an individual.
Is palonosetron currently in shortage?
Yes, palonosetron is currently listed as to be discontinued by the FDA. Affected manufacturer: Teva Pharmaceuticals USA, Inc.. Visit the FDA Drug Shortages database for the latest updates.

Other drugs grouped near palonosetron - same-class peers and common alternatives.

Compare palonosetron vs alosetron side-by-side →

Compare beyond drug class

Nationwide peers by FAERS volume & death-report share

Two PlainMeds-derived comparison paths for palonosetron: nearest FDA FAERS report volume and nearest death-report share among drugs with at least 1,000 logged reports, excluding same-class neighbors listed above. Counts reflect reporting volume, not proven individual harm.

Medication Guides

Save on palonosetron

Compare prices and find discounts at pharmacies near you. Free coupons can save up to 80% on prescriptions.

Disclosure: This link may earn us a commission at no extra cost to you. See our terms.

What the FDA Data Shows for palonosetron

The FDA label for palonosetron (sold under brand names such as Aloxi) classifies it as a prescription-only medication in the 5-HT3 Receptor Antagonist (Antiemetic) class. Palonosetron is used to prevent nausea and vomiting caused by cancer chemotherapy. Official labeling lists 2 commonly reported side effects, including Headache, Constipation.

Post-market surveillance from the FDA Adverse Event Reporting System (FAERS) captures real-world experience. For this drug, FAERS contains 3,330 voluntary reports. Interaction data is drawn directly from FDA-approved prescribing information. Acquisition-cost data is surveyed weekly by CMS and updated as manufacturers report changes.

Report counts do not establish causation, a FAERS entry documents a temporal association, not proof that the drug produced the outcome. Widely prescribed medications naturally accumulate more reports than niche therapies, so raw totals must be interpreted alongside total exposure. Shortage status, recall history, and patent information are separate source-record fields. This page is a public FDA/CMS registry and does not provide medical, treatment, substitution, or medication-change directions.

Data Sources

Drug labeling: FDA Drug Labels (SPL/DailyMed). Adverse events: FDA Adverse Event Reporting System (FAERS). Shortage status: FDA Drug Shortages Database.

FAERS reports are voluntary and do not establish causation. Drug interactions are derived from FDA labeling and clinical references. This registry does not provide medication decisions.

Last updated: May 15, 2024

PlainMeds is rendered directly from FDA openFDA/FAERS extracts, DailyMed labels, and CMS drug-pricing files, no number is typed in by an editor. FAERS counts, recalls, shortages, and price figures on this page are queried live from those federal extracts. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-05-15. Primary sources: openFDA / FAERS, DailyMed and CMS Part B ASP.

Data currency: FDA FAERS adverse-event reports through 2025, CMS NADAC acquisition-cost pricing effective December 2024, compiled from the source snapshot dated . See our methodology for per-source dates and refresh cadence. Spot a figure that looks wrong? Report a data issue.

All federal data sources used on this page